Oct 7, 2021 7:00 am EDT Ocuphire Announces Publications Featuring the Ref-1 Protein, a Transcription Factor Regulator, as a Novel Therapeutic Target for the Treatment of Neovascular Retinal Diseases
Oct 1, 2021 8:49 am EDT Ocuphire’s Clinical Phase 2b Oral Drug Candidate APX3330 for Retina to be Featured at the OIS Retina@ASRS and ASRS 2021 Annual Meeting
Sep 27, 2021 7:00 am EDT Ocuphire Pharma Presenting at Three Upcoming Healthcare Conferences This Fall
Sep 22, 2021 7:30 am EDT RD Fund Launches Opus Genetics with $19M Seed Funding to Advance Gene Therapy Treatments for Blinding Conditions
Sep 3, 2021 5:00 pm EDT Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Aug 12, 2021 7:00 am EDT Ocuphire Announces Financial Results for the Second Quarter 2021 and Provides Corporate Update
Jul 22, 2021 8:00 am EDT Ocuphire Announces Publication in the Journal of Cellular Signaling Featuring its Oral Ref-1 Inhibitor APX3330 in Phase 2 Trial for the Treatment of Retinal Disease